Get started
Author

Kunlatida Maneenil

Observed names: K. Maneenil, Maneenil, Kunlatida
ORCID: 0009-0004-0194-4860
Observed ORCID: 0009-0004-0194-4860
OpenAlex ID: A5015511703
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2023 · Shukui Qin, Minshan Chen, et al. · The Lancet · 559
PDF
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
2024 · B. Sangro, S.L. Chan, et al. · Annals of Oncology · 379
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
2025 · Bruno Sangro, Masatoshi Kudo, et al. · The Lancet · 339
PDF
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients
2017 · Kunlatida Maneenil, Zhiqiang Xue, et al. · Clinical Lung Cancer · 98
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide
2019 · Piyawan Tienchaiananda, Wipada Nipondhkit, et al. · Annals of Palliative Medicine · 37
Hepatitis C infection and renal cell carcinoma: A systematic review and meta-analysis
2016 · Karn Wijarnpreecha, Pitchaphon Nissaisorakarn, et al. · World Journal of Gastrointestinal Pathophysiology · 26
PDF
Factors influencing development and mortality of acute respiratory failure in hospitalized patient with active pulmonary tuberculosis: a 10-year retrospective review
2016 · Rungsun Bhurayanontachai, Kunlatida Maneenil · Journal of Thoracic Disease · 22
PDF
Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand
2023 · Korawan Chawalitmongkol, Kunlatida Maneenil, et al. · Journal of the ASEAN Federation of Endocrine Societies · 6
PDF
Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
2021 · Krittiya Korphaisarn, Pongwut Danchaivijitr, et al. · Frontiers in Oncology · 6
PDF
Timing of chronic obstructive pulmonary disease diagnosis in lung cancer prognosis: a clinical and genomic-based study
2021 · Jie Dai, Yanqi He, et al. · Translational Lung Cancer Research · 6
PDF
Survival and Prognostic Factors of Metastatic Breast Cancer.
2017 · Sudsawat Laohavinij, Vinai Paul, et al. · PubMed · 6
P1.07-045 Characteristics of Exceptional Long Term Survivors in Extensive Stage Small Cell Lung Cancer
2017 · Kunlatida Maneenil, Julian Molina, et al. · Journal of Thoracic Oncology · 6
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
2026 · Masatoshi Kudo, Ghassan K Abou-Alfa, et al. · The Lancet Oncology · 2
Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study
2025 · Piyada Sitthideatphaiboon, Thanyanan Reungwetwattana, et al. · Frontiers in Oncology · 2
PDF
Body weight change in a medical supplement group in patients with early breast cancer during chemotherapy: a randomized, controlled trial
2025 · Piyawan Tienchaiananda, Meitinarth Juntong, et al. · Supportive Care in Cancer · 2
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
2026 · Edurne Arriola, Ignacio Casarini, et al. · European Journal of Cancer · 1
1302P Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
2023 · P. Sitthideatphaiboon, T. Reungwetwattana, et al. · Annals of Oncology · 1
PDF
Survival and prognostic factors in cholangiocarcinoma: A single-center experience
2019 · S. Payapwattanawong, K. Maneenil, et al. · Annals of Oncology · 1
Landscape of industry-sponsored oncology trials across the Thai Society of Clinical Oncology (TSCO): a 12-year multicenter analysis
2026 · Kosin Wirasorn, Jirapath Wiwitkeyoonwong, et al. · BMC Cancer
Efficacy of surgical glove-compression therapy as a prevention of paclitaxel-induced peripheral neuropathy: Randomized controlled trial.
2026 · Saowani Thantaviraya, Sunatee Sa-nguansai, et al. · Journal of Clinical Oncology
PDF
Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study
2026 · Krittiya Korphaisarn, Kosin Wirasorn, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
1151P Landscape and performance of industry-sponsored oncology trials in Thailand: A Thai Society of Clinical Oncology (TSCO) multicenter analysis
2025 · J. Juengsamarn, J. Wiwitkeyoonwong, et al. · Annals of Oncology
Oncological outcomes of neoadjuvant chemotherapy in muscle-invasive bladder cancer in Rajavithi Hospital
2025 · Sittisorn, Worawit, Thaidumrong, Tanet, et al. · Insight Urology
PDF
201P: Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)
2025 · E. Arriola Aperribay, I. Casarini, et al. · Journal of Thoracic Oncology
PDF
Real-world data of durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: A Thailand multicenter observational study.
2025 · Suebpong Tanasanvimon, Kunlatida Maneenil, et al. · Journal of Clinical Oncology
Works count: 37
Citation count: 1,499
H-index: 7
I10-index: 7
Year
Topic
Type